◼ Archived
Business
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 trends tracked about this subject — the full history, oldest to newest below.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.
Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.